Institutional development · Research, innovation and assessment · Switzerland
USI-affiliated IOR team identifies possible route to therapy resistance in B-cell lymphomas
A lymphoma genomics group at the Institute of Oncology Research, affiliated with Università della Svizzera italiana, reports a possible mechanism behind treatment resistance in some B-cell lymphomas.
Why it matters: The finding comes from the Lymphoma Genomics group led by Francesco Bertoni at IOR, an institute affiliated with USI and a member of Bios⁺.
According to Università della Svizzera italiana (USI), the Lymphoma Genomics research group at the Institute of Oncology Research (IOR) has identified a possible mechanism that lets some B-cell lymphomas become resistant to therapies.
USI said the group is directed by Professor Francesco Bertoni at IOR.
The university describes IOR as affiliated with USI and as a member of Bios⁺.
Editor’s view
Scott James, Research and Innovation Editor
The reported result is described as a possible mechanism of resistance in some B-cell lymphomas, identified by the IOR group led by Francesco Bertoni.
